By Dhirendra Tripathi

Investing.com – Pfizer Stock (NYSE:) rose 0.4% on Thursday after the U.S. placed an order for 10 million Covid-19 treatment courses at $5.29B to purchase the stock.

Although the Food and Drug Administration still has not approved the pill, supplies will be available by 2022 once they are.

It also stated that it had entered into bilateral agreements with over 100 other nations and that they have made advance purchases.

The effectiveness of the antiviral pills against Covid-19 has been proven by only three oral medications. Pfizer says that it can reduce hospitalizations and deaths by 89%. Merck’s molnupiravir was developed with Ridgeback Biotherapeutics and boasts an efficiency ratio just above 50%.   

Pfizer raised its guidance recently, mainly relying on the sales of Comirnaty to increase sales. Pfizer now expects to make $81.5 billion in 2021, which is the middle of its range of forecasts. This includes $36 billion from sales of Covid-19. It’s $2.5billion more than in the last forecast.

The pill is seen as the second winner in the company’s Covid portfolio that is now looking at approvals to its booster dose to lend more strength to the sales.

The company is awaiting the outcome of today’s meeting of FDA experts who will discuss the merits of a third shot for all adults. So far, only those at least 65 or vulnerable are eligible for a third shot of the company’s vaccine.

Center for Disease Control and Prevention’s independent committee will meet Friday to discuss the same.

The company is offering generic manufacturing rights for the drug, while allowing them to sell it in the low and middle income countries.